January 2005 in “Digital Access to Scholarship at Harvard (DASH) (Harvard University)” This article examines how the Dietary Supplement Health and Education Act of 1994 allows ineffective herbal remedies for hair loss to remain on the market, potentially misleading consumers, and suggests possible solutions.
1 citations
,
January 2013 in “Scholar Commons (University of South Carolina)” This article discusses the regulatory gap in updating labeling responsibilities for generic drugs and argues for the FDA to use negotiated rulemaking to develop more effective drug regulations, but provides no new empirical results.
2 citations
,
January 2019 in “Applied clinical research, clinical trials and regulatory affairs” This review discusses the regulations and clinical safety aspects of hair care cosmetics, highlighting the FDA's recommendation to evaluate these products for allergic reactions, avoid contamination, and include antimicrobial agents to ensure consumer safety, with ongoing monitoring through consumer feedback.
10 citations
,
June 2016 in “PLOS ONE” In this in-vitro study, researchers identified finasteride as the most effective FDA-approved drug for expanding functional myeloid-derived suppressor cells, suggesting its potential future use in immunosuppressive therapies.
1 citations
,
May 2023 in “Biochemical and Biophysical Research Communications” This study found that DKK1-targeting siRNA, which may activate the Wnt/β-catenin signaling pathway, showed hair growth results in mice similar to those treated with the FDA-approved minoxidil, suggesting potential as an androgenetic alopecia therapy.